MARÍA MAGDALENA
SALCEDO PLAZA
Profesora asociada de Ciencias de la Salud
Hospital Universitari de Bellvitge
l'Hospitalet de Llobregat, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitari de Bellvitge (21)
2024
-
The role of HBIG in real life for patients undergoing liver transplantation due to HDV-related cirrhosis
Liver International, Vol. 44, Núm. 2, pp. 279-285
2022
-
Cumulative exposure to tacrolimus and incidence of cancer after liver transplantation
American Journal of Transplantation, Vol. 22, Núm. 6, pp. 1671-1682
-
Decreased Long-Term Severe Acute Respiratory Syndrome Coronavirus 2–Specific Humoral Immunity in Liver Transplantation Recipients 12 Months After Coronavirus Disease 2019
Liver Transplantation, Vol. 28, Núm. 6, pp. 1039-1050
-
Sinusoidal obstruction syndrome after liver transplantation: A multicenter observational study
Liver Transplantation, Vol. 28, Núm. 7, pp. 1257-1261
2021
-
COVID-19 in Solid Organ Transplant Recipients in Spain Throughout 2020: Catching the Wave?
Transplantation, Vol. 105, Núm. 10, pp. 2146-2155
-
Changes in humoral immune response after SARS-CoV-2 infection in liver transplant recipients compared to immunocompetent patients
American Journal of Transplantation, Vol. 21, Núm. 8, pp. 2876-2884
-
Epidemiological pattern, incidence, and outcomes of COVID-19 in liver transplant patients
Journal of Hepatology, Vol. 74, Núm. 1, pp. 148-155
-
Tacrolimus as an Effective and Durable Second-Line Treatment for Chronic Autoimmune Hepatitis: A Multicentric Study
Digestive Diseases and Sciences, Vol. 66, Núm. 8, pp. 2826-2832
2020
-
Preliminary Results of a Randomized Clinical Trial of Intravenous Immunoglobulin in Solid Organ Recipients with Severe Infection and Secondary Antibody Deficiency
The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, Vol. 39, Núm. 4, pp. S45-S46
2017
-
Clinical outcomes of patients undergoing antiviral therapy while awaiting liver transplantation
Journal of Hepatology, Vol. 67, Núm. 6, pp. 1168-1176
-
Efficacy and safety of daclatasvir-based antiviral therapy in hepatitis C virus recurrence after liver transplantation. Role of cirrhosis and genotype 3. A multicenter cohort study
Transplant International, Vol. 30, Núm. 10, pp. 1041-1050
-
Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease: Analysis of data from the Hepa-C registry
Hepatology, Vol. 65, Núm. 6, pp. 1810-1822
2016
-
Impact of cytomegalovirus infection on severe hepatitis c recurrence in patients undergoing liver transplantation
Transplantation, Vol. 100, Núm. 3, pp. 593-599
-
Liver Retransplantation in Patients with HIV-1 Infection: An International Multicenter Cohort Study
American Journal of Transplantation, Vol. 16, Núm. 2, pp. 679-687
2015
-
Current preventive strategies and management of Epstein-Barr virus-related post-transplant lymphoproliferative disease in solid organ transplantation in Europe. Results of the ESGICH Questionnaire-based Cross-sectional Survey
Clinical Microbiology and Infection, Vol. 21, Núm. 6, pp. 604.e1-604.e9
-
Renal function improvement in liver transplant recipients after early everolimus conversion: A clinical practice cohort study in Spain
Liver Transplantation, Vol. 21, Núm. 8, pp. 1056-1065
-
V Reunión de Consenso de la Sociedad Española de Trasplante Hepático sobre receptores de riesgo elevado, escenarios actuales de inmunosupresión y manejo del hepatocarcinoma en espera de trasplante
Cirugia Espanola, Vol. 93, Núm. 10, pp. 619-637
2013
-
Impact of donor and recipient CYP3A5 and ABCB1 genetic polymorphisms on tacrolimus dosage requirements and rejection in caucasian spanish liver transplant patients
Journal of Clinical Pharmacology, Vol. 53, Núm. 11, pp. 1146-1154
2012
-
Epidemiology and outcome of infections in human immunodeficiency virus/hepatitis c virus-coinfected liver transplant recipients: A FIPSE/GESIDA Prospective Cohort Study
Liver Transplantation, Vol. 18, Núm. 1, pp. 70-81
2011
-
Cyclosporine A-based immunosuppression reduces relapse rate after antiviral therapy in transplanted patients with hepatitis C virus infection: A large multicenter cohort study
Transplantation, Vol. 92, Núm. 3, pp. 334-340